Beranda › Kanker Paru Non-Sel Kecil › Maryland › Baltimore
Uji klinis Kanker Paru Non-Sel Kecil di Baltimore, MD
60 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Baltimore (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- dan 4 lainnya
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Local Institution - 0123, Baltimore
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Menerima pesertaFase 3
- Ascension Saint Agnes Hospital, Baltimore
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 1/2
- Research Site, Baltimore
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #14, Baltimore
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Menerima pesertaFase 2
- MedStar Franklin Square Medical Center ( Site 0033), Baltimore
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- Johns Hopkins University, Baltimore
DK222 Study at Hopkins
Menerima pesertaFase 1
- Johns Hopkins Hospital, Baltimore
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Menerima pesertaFase 3
- Johns Hopkins University of Medicine, Baltimore
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Menerima pesertaFase 2
- Sidney Kimmel Cancer Center - Bayview Campus, Baltimore
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- Maryland Oncology Hematology, P.A., Annapolis · 22 mi jauhnya
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Research Site, Towson · 8 mi jauhnya
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Maryland Oncology Hematology, P.A., Annapolis · 22 mi jauhnya
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- University of Maryland, Baltimore
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- University of Maryland, Baltimore
- Johns Hopkins Bayview Medical Center, Baltimore
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Menerima pesertaFase 3
- Research Site, Annapolis · 22 mi jauhnya
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Menerima pesertaFase 2
- Research Site, Baltimore
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Menerima pesertaFase 3
- Local Institution - 0505, Annapolis · 22 mi jauhnya
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Menerima pesertaFase 3
- Local Institution - 0702, Annapolis · 22 mi jauhnya
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Menerima pesertaFase 2
- University of Maryland Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Medstar Franklin Square, Baltimore
- dan 1 lainnya
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Menerima pesertaFase 3
- Clinical Study Site, Baltimore
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Menerima pesertaFase 1
- Johns Hopkins, Baltimore
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Menerima pesertaFase 1
- United Theranostics, Glen Burnie · 9 mi jauhnya
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Menerima pesertaFase 2/3
- The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Menerima pesertaFase 2
- John Hopkins Medical Center, Baltimore
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Johns Hopkins Bayview Medical Center, Baltimore
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Saint Agnes Hospital - Baltimore - Hunt - PPDS, Baltimore
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Menerima pesertaFase 3
- Research Site, Baltimore
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Menerima pesertaFase 1
- University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Menerima pesertaFase 3
- University of Maryland, Baltimore
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Menerima pesertaFase 2
- MedStar Franklin Square Medical Center ( Site 0033), Baltimore
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Menerima pesertaFase 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Menerima pesertaFase 1/2
- Johns Hopkins University, Baltimore
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Menerima pesertaFase 1
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Menerima pesertaFase 1
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Menerima pesertaFase 1
- Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Menerima pesertaFase 1/2
- University of Maryland, Baltimore
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Research Site, Baltimore
GCC 2546- Motion Management
Menerima peserta
- University of Maryland Greenebaum Cancer Center, Baltimore
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Menerima pesertaFase 1
- Advanced Molecular Imaging and Therapy, Glen Burnie · 9 mi jauhnya
- United Theranostics - Chesapeake, Glen Burnie · 9 mi jauhnya
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Menerima pesertaFase 1
- Johns Hopkins Hospital /ID# 254056, Baltimore
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · 9 mi jauhnya
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- Johns Hopkins University, Baltimore
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Menerima pesertaFase 1/2
- Johns Hopkins Hospital, Baltimore
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Menerima pesertaFase 1/2
- Johns Hopkins University, Baltimore
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Research Site, Baltimore
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
Menerima pesertaFase 1
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- Baltimore Washington Medical Center- Tate Cancer Center, Glen Burnie · 9 mi jauhnya
- dan 1 lainnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Saint Agnes Hospital, Baltimore
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · 9 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · 9 mi jauhnya
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Menerima pesertaFase 2
- University of Maryland Medical Center, Baltimore
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Menerima pesertaFase 1/2
- Johns Hopkins University, Baltimore
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Menerima pesertaFase 1
- Research Site, Baltimore
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
Menerima pesertaFase 1
- Johns Hopkins University, Baltimore
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- UM Saint Joseph Medical Center, Towson · 8 mi jauhnya
- dan 1 lainnya
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Menerima pesertaFase 2
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
- Harry and Jeannette Weinberg Cancer Institute at Franklin Square, Baltimore
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Menerima peserta
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
GEMINI-NSCLC: NSCLC Biomarker Study
Menerima pesertaStudi observasional
- University of Maryland, Baltimore
- Johns Hopkins University, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · 8 mi jauhnya
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Menerima pesertaFase 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
- Seattle, WA53 studi
Studi lain di Baltimore
- Kanker Payudara47 studi
- Kanker Prostat43 studi
- Kanker Paru40 studi
- Kanker (semua jenis)37 studi
- Kanker Pankreas31 studi
- Kanker Kolorektal31 studi
- Kanker Metastatik28 studi
- Obesitas26 studi
- Kanker Kandung Kemih24 studi
- Gagal Jantung24 studi
- Kanker Ovarium22 studi
- Stroke21 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.